|
[1] 张丹,牟尚东,田姗,等 . 吉非替尼治疗非小细胞肺癌的效果分析及其机制研究[J]. 中国医药,2020,15(3):366-369. DOI:
10.3760/j.issn.1673-4777.2020.03.011.
[2] 苍宏宇,梁润,高维实 . 上皮生长因子受体(EGFR)靶向治疗药物(易瑞沙)治疗非小细胞肺癌的疗效及影响因素[J]. 实
用 癌 症 杂 志 , 2018, 33(9): 1421-1423. DOI: 10.3969/j.
issn.1001-5930.2018.09.009.
[3] 顾爱琴,高志强,王慧敏,等 . 吉非替尼单药治疗晚期非小细胞肺癌老年患者的临床分析[J]. 上海交通大学学报(医学
版),2011,31(3):305-308. DOI:10.3969/j.issn.1674-8115.
2011.03.013.
[4] 罗长琴,王丽娜,李雨遥,等 . 吉非替尼致间质性肺炎并文献回顾 [J]. 现代肿瘤医学 , 2012, 20(9): 1858-1862. DOI:
10.3969/j.issn.1672-4992.2012.09.30.
[5] Chou CL, Ko HW, Wang CW, et al. Erlotinib-associated
near-fatal interstitial pneumonitis in a patient with
relapsed lung adenocarcinoma[J].Chang Gung Med J,2010,
33(1):100-105.
[6] Min JH, Lee HY, Lim H, et al. Drug-induced interstitial lung
disease in tyrosine kinase inhibitor therapy for non-small
cell lung cancer: a review on current insight[J]. Cancer
Chemother Pharmacol, 2011, 68(5): 1099-1109. DOI:
10.1007/s00280-011-1737-2.
[7] Ishiguro Y, Ishiguro H, Miyamoto H. Epidermal growth
factor receptor tyrosine kinase inhibition up-regulates
interleukin-6 in cancer cells and induces subsequent
development of interstitial pneumonia[J]. Oncotarget,
2013,4(4):550-559. DOI:10.18632/oncotarget.939.
[8] Namba T, Tanaka K, Hoshino T, et al. Suppression of
expression of heat shock protein 70 by gefitinib and its
contribution to pulmonary fibrosis[J]. PLoS One, 2011,
6(11):e27296. DOI:10.1371/journal.pone.0027296.
[9] Uchida M, Shiraishi H, Ohta S, et al. Periostin, a
matricellular protein, plays a role in the induction of
chemokines in pulmonary fibrosis[J].Am J Respir Cell Mol
Biol, 2012, 46(5): 677-686. DOI: 10.1165/rcmb. 2011-
0115OC.
[10] Suzuki R, Hasegawa Y, Baba K, et al. A phase II study of
single-agent gefitinib as first-line therapy in patients with
stage IV non-small-cell lung cancer[J]. Br J Cancer, 2006,
94(11):1599-1603. DOI:10.1038/sj.bjc.6603159.
[11] 程双慧,王旭,郭晔,等 . 吉非替尼治疗非小细胞肺癌致间质性肺炎的研究进展[J]. 中国老年学杂志, 2018, 38(20):
5096-5099. DOI:10.3969/j.issn.1005-9202.2018.20.087.
[12] 田宏 . EGFR-TKI 致肝损伤的研究进展[J]. 中国医学创新,
2015, 12(4): 152-156. DOI: 10.3969/j. issn. 1674-4985.
2015. 04.051.
[13] 杜俊,王征,杨丽,等 . 肺腺癌患者血浆和肿瘤标本中表皮生长因子受体基因T790M位点突变检测一致性研究[J]. 中华肿瘤杂志 , 2018, 40(1): 35-39. DOI: 10.3760/cma. j.
issn.0253?3766.2018.01.006.
[14] Li J, Wang XH, Hu J, et al. Combined treatment with
N-acetylcysteine and gefitinib overcomes drug resistance
to gefitinib in NSCLC cell line[J]. Cancer Med, 2020, 9(4):
1495-1502. DOI:10.1002/cam4.2610.
|
